Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology Pinecast (https://pinecast.com) en-US@Point of Care @Point of Care atpointofcare@gmail.com no Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology https://storage.pinecast.net/podcasts/covers/54dff532-909d-4fc8-852b-66c58aef3572/HematologyOncology.png episodic Copyright 2020 At Point of Care, LLC. All rights reserved. https://pinecast.com/feed/oncology-point-of-care-podcast S29:E1 – TROP2 ADCs in NSCLC: Mechanisms and Management https://pinecast.com/guid/071b6d5b-cc0e-4157-a94b-6dc6c1c3accd Tue, 30 Jun 2026 04:00:00 -0000 00:33:43 https://www.atpointofcare.com/library/2730.11/page/0 In this episode, Dr. Kristen Marrone and nurse practitioner Beth Sandy discuss the mechanism and clinical evidence supporting TROP2-directed ADCs, emerging agents and combinations, and ongoing biomarker development to optimize patient selection.

Visit TROP2 ADCs in NSCLC: Mechanisms and ManTROP2 ADCs in NSCLC: Mechanisms and Managementagement to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> TROP2 ADCs in NSCLC: Mechanisms and Management no 29 1 Managing Toxicities With TROP2-Targeting ADCs for NSCLC https://pinecast.com/guid/3ac3856c-c489-4fcd-8d07-60a9e3932e47 Tue, 30 Jun 2026 04:00:00 -0000 00:29:05 https://www.atpointofcare.com/library/2730.12/page/0 In this episode, Dr. Kristen Marrone and nurse practitioner Beth Sandy discuss strategies for preventing the key adverse effects associated with datopotamab deruxtecan (Dato-DXd), including stomatitis, ocular toxicities, and drug-induced interstitial lung disease/pneumonitis.

Visit Managing Toxicities With TROP2-Targeting ADCs for NSCLC to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> no 29 S28:E2 – Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS https://pinecast.com/guid/a7e84695-b8bc-4972-a1b3-4b8fc2878280 Fri, 24 Apr 2026 04:10:00 -0000 00:30:20 https://suitehome.atpointofcare.com/library/2729.02/page/0 In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS they review the clinical trial and real-world evidence on the efficacy and safety of currently available therapies for patients with lower-risk myelodysplastic syndrome (LR-MDS)-associated anemia. Their thought-provoking discussion will give an overview of the pertinent publications while highlighting the clinical implications of this data, in practice. 

Visit https://suitehome.atpointofcare.com/library/2729.02/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS no 28 2 S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS https://pinecast.com/guid/24cb6932-57fd-47d5-b3be-e67072b7c8f4 Fri, 24 Apr 2026 04:00:00 -0000 00:23:28 https://suitehome.atpointofcare.com/library/2729.01/page/0 In this podcast episode, Andrew Kuykendall, MD,  and Sangeetha Venugopal, MD, MS explore dose escalation strategies for the erythroid maturation agent (EMA), luspatercept, in patients with lower-risk myelodysplastic syndrome (LR-MDS). Their engaging discussion will give an overview of the pertinent clinical trial efficacy and safety data and recent changes to the prescribing information, as well as delving into how they both apply this information in their clinical practices.

Visit https://suitehome.atpointofcare.com/library/2729.01/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn

]]> Clearing the Confusion on Dosing for Luspatercept in LR-MDS no 28 1 S27:E3 – Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs https://pinecast.com/guid/ae08b184-ecaf-45c3-aef8-9fab9f25587d Thu, 15 Jan 2026 05:20:00 -0000 00:30:38 https://suitehome.atpointofcare.com/library/2720.03/page/0 In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs). 

Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs no 27 3 S27:E2 – TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib https://pinecast.com/guid/94a22bad-9e2d-49dd-b748-79cd70218e39 Thu, 15 Jan 2026 05:10:00 -0000 00:28:36 https://suitehome.atpointofcare.com/library/2720.02/page/0 In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC; 2) quantitative continuous scoring (QCS) as a predictive biomarker; 3) current efficacy and safety data from clinical trials; and 4) best practices for monitoring and mitigating ADC-associated toxicities. 

Visit https://suitehome.atpointofcare.com/library/2720.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib no 27 2 S27:E1 – HER2-Directed ADCs in Advanced NSCLC https://pinecast.com/guid/e5a0a203-de19-4b68-9205-b75c1806e9e4 Thu, 15 Jan 2026 05:00:00 -0000 00:24:44 https://suitehome.atpointofcare.com/library/2720.01/page/0 In this episode, medical oncologist Dr. Charu Aggarwal and nurse practitioner Beth Sandy explore human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates (ADCs) in the management of advanced non-small cell lung cancer. Their engaging discussion will include topics such as HER2 biomarker testing, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated toxicities. 

Visit https://suitehome.atpointofcare.com/library/2720.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> HER2-Directed ADCs in Advanced NSCLC no 27 1 S26:E3 – Rewriting the ET Playbook https://pinecast.com/guid/796125fe-a01f-479b-8bfc-4d50a9462e5d Fri, 31 Oct 2025 15:00:00 -0000 00:25:02 https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 In this episode, Rewriting the ET Playbook, Dr. Douglas Tremblay and Dr. Ruben Mesa review the current therapeutic options for treating essential thrombocythemia, and they review therapies on the horizon that are currently in late-stage clinical trials. What do clinicians need to know for managing this blood disorder?

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Rewriting the ET Playbook no 26 3 S26:E2 – Treatment Success in PV https://pinecast.com/guid/0228630d-c461-45a6-b239-9e269ca5a635 Fri, 31 Oct 2025 14:00:00 -0000 00:26:13 https://suiteweb.atpointofcare.com/#library/mpn/2718.02/page/0 In this episode, Treatment Success in PV, Dr. Douglas Tremblay and Dr. Ruben Mesa focus on the goals of therapy for polycythemia vera, namely improving symptom burden and reducing thrombosis.

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Treatment Success in PV no 26 2 S26:E1 – From Clues to Classification: PV and ET Diagnosis and Risk Stratification https://pinecast.com/guid/e4483cc8-0b14-4119-ad48-73fbe4b3c6b6 Fri, 31 Oct 2025 13:00:00 -0000 00:29:08 https://suiteweb.atpointofcare.com/#library/mpn/2718.01/page/0 In this episode, From Clues to Classification, PV and ET Diagnosis Risk Stratification, Dr. Douglas Tremblay and Dr. Ruben Mesa discuss how clinicians can make an accurate diagnosis for these two blood disorders and how to prevent vascular complications, particularly how risk stratification can guide therapeutic shared decision-making.

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> From Clues to Classification: PV and ET Diagnosis and Risk Stratification no 26 1